Chemotherapy

Photo

Article • Assessing chemotherapy

Ultrasound presents an alternative to radiation

Injecting toxic chemicals into the body to kill cancer cells is a physically and mentally brutal experience for patients. The treatment cost is equally brutal for healthcare systems. Yet, often after six months of difficult treatment, patients may hear that the chemotherapy did not stop or kill the cancer. There is now a way to find out, in just 30 days and at a cost of just €183, whether the…

Italy’s first proton therapy centre

Agenzia Provinciale Per la Protonterapia (ATreP) has signed a contract with Ion Beam Applications S.A. (IBA), based in Luvain-La-Neuve, Belgium, for the installation of a proton therapy centre in a new hospital planned for Trento. Over the next 15 years, IBA will provide the construction, installation and technical operation of this the first gantry-equipped proton therapy-dedicated centre in…

Photo

PET/CT Predicts Early Response to Chemotherapy

That wait time might be shortened for patients with soft-tissue sarcomas thanks to new research, from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), demonstrating that PET/CT can be used as early as one week after a single treatment cycle to determine whether the drugs are killing the cancer. Researchers made another surprising discovery—some tumors…

Photo

Human papilloma viral infection

A global vaccination programme against human papilloma virus (HPV), to include boys as well as girls, could lead to eradication of the virus and virtual disappearance of cervical cancer, according to Nobel Prize winner, Professor Emeritus Harald zur Hausen (University of California, San Diego) after recently delivering a keynote lecture at the 16th International Meeting of the European Society of…

Biochips to aid in cancer diagnosis

It is very difficult to predict whether a cancer drug will help an individual patient: only around one third of drugs will work directly in a given patient. Researchers at the Heinz Nixdorf Chair for Medical Electronics at the Technische Universitaet Muenchen (TUM) have developed a new test process for cancer drugs. With the help of microchips, they can establish in the laboratory whether a…

New horizons in Nuclear Medicine therapy

Radionuclide therapy has been rapidly developing for the last 20 years, due to the availability of new carrier molecules and radionuclides. For some years the clinical efficacy has been modest with a low percentage of objective responses and no survival benefit because, most often, the patients had large tumor burden.

Nobel scientist urges wider vaccination against HPV infection

A global vaccination programme against human papilloma virus (HPV), to include boys as well as girls, could lead to eradication of the virus and virtual disappearance of cervical cancer, predicted Nobel Prize winner, Professor Harald zur Hausen, after delivering the key-note lecture at the 16th International Meeting of the European Society of Gynaecological Oncology (ESGO) in Belgrade, Serbia,…

J&J acquires Cougar

Positive CB7630 (Abiraterone Acetate) Phase II Data was presented at the ASCO Annual Meeting in Chicago this May/June, Cougar Biotechnology Inc, a development stage biopharmaceutical firm with a specific focus on oncology. In mid-July, Johnson & Johnson announced its acquisition of Cougar, which is now working with Ortho Biotech Oncology Research & Development, a division of the J&J firm Centocor…

MINDACT

Researchers around the globe are studying whether a genomic test, developed with micro-array technology, is superior to traditional methods in assessing aggressive breast cancer, and therefore could spare a considerable percentage of women from the onslaught of chemotherapy The Breast International Group (BIG) in Brussels, Belgium, manages TRANSBIG, an international network created to avoid…

20 show more articles
Subscribe to Newsletter